Benjamin Morin

Benjamin Morin has extensive work experience in the field of virology, with a focus on RNA viruses. Benjamin started their career as a Ph.D. student at CNRS, where they conducted structural and functional studies on RNA virus proteins involved in viral replication and cellular response against infection. Benjamin made significant contributions to the field by solving the first crystal structure of a negative-strand L polymerase domain and identifying it as a validated target for antiviral research. Additionally, they developed a method to produce signaling molecules in the induction of the interferon response and crystallized the alphavirus nsp3 in complex with a potential inhibitor of the cellular response against infection.

After completing their Ph.D., Morin joined Harvard Medical School as a Postdoctoral Fellow, where they continued their research on non-segmented negative-strand RNA viruses such as measles, rabies, and Ebola. Benjamin developed novel in vitro assays to study the mechanism of RNA synthesis initiation and identified previously unknown functions of the replicative machinery partners in RNA synthesis. Benjamin also led collaborative projects with academic and industry partners for the discovery of new inhibitors of the replicative machinery.

Currently, Morin is working at Agenus as the Director of Preclinical R&D. Prior to this role, they held positions as the Associate Director/Head of Biochemistry and Scientist II. Although specific details about their responsibilities in these roles are not provided, it can be inferred that their expertise in virology and drug discovery was utilized.

Overall, Morin's work experience demonstrates their expertise in virology, specifically in the study of RNA viruses, structural biology, and drug discovery. Benjamin has made significant contributions to the field through their research, publications, and collaborations.

Benjamin Morin pursued their education in the field of Bioinformatics, structural biochemistry, and genomics. Benjamin completed their Master's degree at Aix-Marseille University from 2004 to 2005. Following this, they went on to obtain a Doctor of Philosophy - PhD from the same institution in the field of Structural Biochemistry, which they completed between 2005 and 2010.